Intraday Price Movement and Trading Range
The stock opened on a positive note with a 2.05% gain, reaching an intraday high of Rs 2,202.70, up 2.17% from the previous close. However, this initial optimism was short-lived as selling intensified, pushing the price down to its intraday low of Rs 2,081, representing a decline of 3.47% from the opening price. The day closed with a loss of 3.17%, marking a significant intraday reversal.
Comparison with Sector and Market Performance
Mankind Pharma’s performance lagged behind the Pharmaceuticals & Biotechnology sector, underperforming by 3.61% on the day. The broader Sensex index also opened lower at 83,252.06, down 487.07 points or 0.58%, and was trading marginally down by 0.08% at 83,671.42 during the stock’s decline. The Sensex remains 2.97% below its 52-week high of 86,159.02, indicating a cautious market environment.
Technical Indicators and Moving Averages
From a technical standpoint, Mankind Pharma is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This positioning suggests a prevailing downward momentum and limited short-term support. The stock is also close to its 52-week low, currently just 1.72% above the Rs 2,050 mark, underscoring the pressure on its price levels.
Strong fundamentals, solid momentum, fair price – This Large Cap from the NBFC sector checks every box for our Top 1%. This should definitely be on your radar!
- - Complete fundamentals package
- - Technical momentum confirmed
- - Reasonable valuation entry
Recent Performance Trends
Examining the stock’s recent performance reveals a consistent pattern of underperformance relative to the Sensex. Over the past day, Mankind Pharma declined by 3.32%, compared to the Sensex’s marginal fall of 0.08%. The one-week trend shows a 1.48% drop for the stock, while the Sensex gained 1.61%. Over one month, the stock fell 5.37%, more than double the Sensex’s 2.44% decline.
Longer-term trends are more pronounced, with the stock down 12.03% over three months and 18.57% over one year, contrasting with the Sensex’s gains of 0.25% and 6.47% respectively. Year-to-date, Mankind Pharma has declined 5.10%, while the Sensex is down 1.82%. Over three, five, and ten years, the stock’s performance has remained flat at 0.00%, whereas the Sensex has delivered substantial gains of 37.52%, 65.31%, and 243.77% respectively.
Market Sentiment and Immediate Pressures
The broader market environment has been cautious, with the Sensex trading below its 50-day moving average, though the 50-day average remains above the 200-day average, indicating a mixed technical backdrop. This environment has contributed to subdued investor appetite for stocks like Mankind Pharma, which face pressure from both sectoral and market-wide factors.
Additionally, the downgrade in the company’s Mojo Grade from Hold to Sell on 19 November 2025, with a current Mojo Score of 38.0, reflects a reassessment of the stock’s outlook by market analysts. The Market Cap Grade remains at 1, signalling limited market capitalisation strength relative to peers. These factors have likely contributed to the stock’s vulnerability to intraday selling pressure.
Considering Mankind Pharma Ltd? Wait! SwitchER has found potentially better options in Pharmaceuticals & Biotechnology and beyond. Compare this large-cap with top-rated alternatives now!
- - Better options discovered
- - Pharmaceuticals & Biotechnology + beyond scope
- - Top-rated alternatives ready
Summary of Price Pressure Factors
The intraday decline in Mankind Pharma’s share price can be attributed to a combination of factors including its proximity to a 52-week low, underperformance relative to sector peers and the broader market, and technical weakness indicated by trading below all major moving averages. The downgrade in the company’s Mojo Grade and low Market Cap Grade further weigh on sentiment.
Market participants appear to be responding to these signals with increased selling, which has resulted in the stock’s intraday low of Rs 2,081. The broader market’s cautious stance, as reflected in the Sensex’s subdued performance, has compounded the pressure on the stock.
Outlook on Market Conditions
While the Sensex remains below its 50-day moving average, the fact that the 50-day average is still above the 200-day average suggests that the market is in a phase of consolidation rather than a full bearish trend. However, this environment has not provided sufficient support for Mankind Pharma to sustain gains, as evidenced by its intraday volatility and closing near day lows.
Investors and market watchers will likely continue to monitor the stock’s technical levels closely, especially its proximity to the 52-week low, as well as any shifts in sectoral dynamics within Pharmaceuticals & Biotechnology that could influence near-term price movements.
Conclusion
Mankind Pharma Ltd’s intraday low on 4 February 2026 highlights the immediate price pressures facing the stock amid a cautious market backdrop. The combination of technical weakness, relative underperformance, and a recent downgrade in rating has contributed to the stock’s decline. The broader market’s subdued tone has further limited upside momentum, resulting in the stock closing near its day’s low despite an initial gap-up opening.
Unlock special upgrade rates for a limited period. Start Saving Now →
